Indefinite Delivery Contract SPE2DR25D9940

Award Date 9/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV award SPE2DR25D9629 is a single-award Indefinite Delivery Contract (IDC) valued at $4,999,999.00 issued by the Defense Logistics Agency (DLA) to the prime contractor DMS Pharmaceutical Group Inc., a woman-owned small business. The contract covers a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military...
The federal contract IDV award SPE2DU25D9514 is a single-award Indefinite Delivery Contract (IDC) between the Defense Logistics Agency (DLA) and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical...
The federal contract IDV award SPE2DU25D9808 is a single-award Indefinite Delivery Contract (IDC) valued at $4,999,999 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract covers a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support the recurring medical supply needs of military...
The federal contract IDV award SPE2DR25D9952 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $4,999,999, covers the delivery of a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply...
The federal contract IDV award SPE2DU25D9335 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical...
The federal contract IDV award is for an Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, provides a vehicle for the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This...
The federal contract IDV award is a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The contract, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications,...
The federal contract IDV award SPE2DR25D9368 is a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 and awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract was awarded by the Defense Logistics Agency (DLA) under the SPE2DB program and covers a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the...
The federal contract IDV award SPE2DR25D9966 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical...
The federal contract IDV award SPE2DR25D9207 was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,999,999 single-award Indefinite Delivery Contract (IDC) enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply...

The federal contract IDV award SPE2DR25D9940 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $4,999,999 contract covers a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

The original contract opportunity was a pre-solicitation for the DLA Troop Support Medical Supply Chain's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts, valued at an estimated $30.3 billion. The intent was to establish multiple primary supplier awards across regional line items (North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet) as well as a backup supplier award, with the goal of ensuring a diverse and resilient pharmaceutical supply chain for the Department of Defense. The contract will have a 30-month base period and three 30-month option periods, and will be awarded on a lowest price technically acceptable basis.

Generated 7/1/25, 12:25 PM